Detailed Scientific Programme
The theme of the 19th St.Gallen International Breast Cancer Conference is “Primary Therapy of Patients with Early Breast Cancer. Evidence, Controversies, Consensus. Individualizing therapy for patients with early-stage breast cancer: tailored local and systemic treatment”.
Programme as of August 2024.
Wednesday, 12 March 2025
Thursday, 13 March 2025
Chairs: David Cameron / Jens Huober / Shigehira Saji (invited)
When can we safely withhold radiotherapy and even surgery?
Charlotte Coles (United Kingdom)
Which older patients truly need chemotherapy?
Hans Wildiers (Belgium)
Pyrrhic victory? Are newer approaches causing more harm than good?
Mafalda Oliveira (Spain)
Discussion Moderator: David Cameron
Chairs: Walter Weber / Zhimin Shao / Monica Morrow
Why should we prevent mastectomies?
Jana de Boniface (Sweden)
Tailoring radiotherapy: Partial breast and hypofractionation, DCIS and molecular markers
Daniela Kauer-Dorner (Austria)
Breast surgery after neoadjuvant systemic treatment
Viviana Galimberti (Italy)
Breast reconstruction and quality of life
Christine Solbach (Germany)
Discussion Moderator: Jana de Boniface
In collaboration with the Chinese Society of Clinical Oncology (CSCO)
Experts from China will present key trials on breast cancer.
Details of the industry sponsored sessions will be published in January 2025.
The SGBCC Academy “Meet the Expert” Sessions allow virtual and on site participants to directly ask their questions to panelists of the St.Gallen Consensus and discuss the most pressing issues in client care faced by physicians around the world.
The panelists featured in the “Meet the Expert” Sessions will be announced in autumn 2024.
Chair: Walter Weber
For: Shelley Potter, Orit Kaidar-Person
Against: Monica Morrow, Philip Poortmans
Chairs: Hal Burstein / Michael Gnant / Meteb Al-Foheidi
Crawling towards cure – small steps of clinical benefit in HR+ (De-escalation, combination, new drugs? SERDs?)
David Cameron (United Kingdom)
Which ER+ tumors still require chemotherapy?
Kevin Kalinski (United States of America)
The long and winding road of individualized endocrine therapy in premenopausal women
Prudence Francis (Australia)
How long is long enough? Duration of endocrine therapy in view of locoregional treatment de-escalation
Terry Mamounas (United States of America)
Lobular breast cancer: unique approaches?
Marie-Jeanne Vrancken-Peeters (The Netherlands)
Multi-omic subtyping and precision-guided therapy of luminal breast cancer
Zhi-Ming Shao (China)
Which tumors warrant adjuvant CDK4/6 inhibitor therapy?
Angela deMichele (United States of America)
Which ER+ cancers will warrant immunotherapy approaches?
Marleen Kok (The Netherlands)
Discussion Moderator: Harold Burstein
Chairs: Fabrice Andre / Nadia Harbeck / Jacob Kather
What is the role of AI in breast pathology?
Jakob Kather (Germany)
What is the role of AI in planning radiation therapy?
Gerd Fastner (Austria)
AI in clinical decision making in EBC: how to build algorithms, validate, and address regulatory/legal concerns
Lisa Carey (United States of America)
Discussion Moderator: Lisa Carey
Chairs: Isabel Rubio / Bahadir Gulluoglu / Eriko Tokunaga (invited)
Where does PET imaging belong in initial staging?
Isabel Rubio (Spain)
What is the role of MRI in the initial presurgical work up?
Bahadir Gulluoglu (Turkey)
Most cancers (lung, colorectal, ovarian, prostate, leukemia, lymphoma) have surveillance studies: is it time to re-think our approach in breast cancer?
Jens Huober (Switzerland)
Discussion Moderator: Bahadir Gulluoglu
Details of the industry sponsored sessions will be published in January 2025.
Friday, 14 March 2025
Saturday, 15 March 2025
Kindly note that the SGBCC Academy “Meet the Expert” Sessions as well as the Voice of China Session will take place in break out rooms. All other sessions will take place in the plenary hall A.
Important Dates
Mark your calender to not miss any of our key dates and deadlines for your attendance and abstract submission to SGBCC 2025!
